COMMUNIQUÉS West-GlobeNewswire

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer
22/08/2025
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer [...]
Repligen Corporation to Present at Upcoming September Conferences
22/08/2025
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming [...]
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
22/08/2025
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]
Trading by management and close relations of management
22/08/2025
Please read the announcement in PDF Attachment 2025_39_Trading_By_Management
Flaggemelding
22/08/2025
Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,36% av aksjene i PCI [...]
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
22/08/2025
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL’s primary listing on the ASX will remain unchanged as a [...]
Financière de Tubize - Convening of the extraordinary general meeting of shareholders of Sep. 24, 2025
22/08/2025
Convening of the Extraordinary General Meeting of shareholders of 24 September 2025 The shareholders are invited to attend the extraordinary general meeting, which will take place on 24 September 2025 at 10:00AM, at [...]
Financière de Tubize - Convocation à l'assemblée générale extraordinaire du 24 septembre 2025
22/08/2025
Convocation des actionnaires à l’Assemblée Générale Extraordinaire du 24 septembre 2025 Les actionnaires sont invités à prendre part à l’assemblée générale extraordinaire qui se tiendra le 24 septembre 2025 à 10 heures [...]
Bavarian Nordic Announces First Half 2025 Results
22/08/2025
COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2025 and released its financial calendar for 2026. Revenue [...]
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
22/08/2025
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with [...]
Renaissance Recovery Expands in Florida, Increasing Capacity and Improving Access to Addiction Treatment
21/08/2025
In response to the growing need for addiction recovery services, Renaissance Recovery is expanding its Florida facility with 16 new available spots. LANTANA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Renaissance Recovery [...]
Regional Health Properties Reports Second Quarter & Six Month 2025 Financial Results
21/08/2025
ATLANTA, GA , Aug. 21, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPB) (OTCQB: RHEPA) (OTCQB:RHEPZ, a self-managed healthcare real [...]
Premier Health Reports 2025 Third Quarter Results
21/08/2025
MONTRÉAL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/08/2025
NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Nusano Cuts Ribbon on State-of-the-Art Radioisotope Production Facility
21/08/2025
Utah Governor Spencer Cox opens 190,000-square-foot building Nusano platform capable of producing more than 40 different radioisotopes for healthcare and industry New supplies of radioisotopes urgently needed for new [...]
BioSyent Releases Financial Results for Q2 and H1 2025
21/08/2025
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2025. Key highlights [...]
BioSyent Declares Third Quarter 2025 Dividend
21/08/2025
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common [...]
Oculis Reports Q2 2025 Financial Results and Provides Company Update
21/08/2025
ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology. OCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with [...]
Oculis Reports Q2 2025 Financial Results and Provides Company Update
21/08/2025
Focused execution in Q2 2025 to advance Oculis’ pipeline in ophthalmology and neuro-ophthalmology OCS-01: Both pivotal Ph3 DIAMOND trials are fully enrolled, with topline results expected in Q2 2026 for the first [...]

Pages